Astim Allerji Immunoloji最新文献_第6页

COVID-19 Disease and Hereditary Angioedema 新冠肺炎疾病与遗传性血管性水肿

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-09-23 DOI: 10.21911/AAI.562

Aycan Aşık, N. Mete Gökmen

引用次数: 3

Childhood Asthma and Covid 19 儿童哮喘与新冠肺炎19

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-09-23 DOI: 10.21911/AAI.561

Ö. Soyer

引用次数: 0

Ecchymosis: An Unexpected Side Effect of Montelukast 瘀血：孟鲁司特的意外副作用

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-09-22 DOI: 10.21911/aai.570

G. Eser, M. Berber, Hülya Ercan Sarıçoban

引用次数: 0

Aerosol Medication Use in COVID-19 Pandemic 新冠肺炎大流行期间气雾剂药物的使用

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-08-15 DOI: 10.21911/aai.539

M. Topel, K. Aksu

引用次数: 0

Bone Metabolism Alterations in Patients with Common Variable Immune Deficiency: A Retrospective Cohort Study 常见可变免疫缺陷患者骨代谢改变:一项回顾性队列研究

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-05-08 DOI: 10.21911/aai.501

G. Aytekin, Fatih Çölkesen, Eray Yıldız, Ş. Arslan, A. Çalışkaner

{"title":"Bone Metabolism Alterations in Patients with Common Variable Immune Deficiency: A Retrospective Cohort Study","authors":"G. Aytekin, Fatih Çölkesen, Eray Yıldız, Ş. Arslan, A. Çalışkaner","doi":"10.21911/aai.501","DOIUrl":"https://doi.org/10.21911/aai.501","url":null,"abstract":"Objective: Common variable immunodeficiency (CVID) is a relatively frequent primary immunodeficiency disorder characterized by impaired B cell differentiation with hypogammaglobulinemia in the European Society for Immunodeficiencies (ESID) registry system. Increased inflammatory cytokines, prolonged and/or recurrent infections, gastrointestinal complications, and anti-inflammatory medications are risk factors for diminished bone mineral density (BMD) in CVID patients. Materials and Methods: The study group included 32 patients with CVID (19 males and 13 females; mean age: 37.33 ± 13.70 years, 40.6% female), who had been followed up on a regular basis for a period of four years. The patients were categorized into two groups according to their BMD: low BMD and normal BMD. Results: Seventeen patients (8 females and 9 males) had normal BMD (mean age 34.94 ± 11.41 years, 47.1% female) and fifteen patients (5 females and 10 males) had low BMD (mean age 40.03 ± 15.87 years, 33.3% female). In the low BMD group, three patients had osteoporosis and 12 patients had osteopenia. Univariate regression analysis revealed that lymphopenia (odds ratio, OR:6.562, 95% confidence interval, CI: 1.095-39.324, p=0.039) was significantly associated with low BMD. Multivariate regression analysis showed that higher alkaline phosphatase (ALP) levels (OR:1.017, 95% CI 1.001-1.033, p=0.041), lymphopenia (OR:11.028, 95% CI 1.326-91.709, p=0.026), and lower folic acid levels (OR:1.284, 95% CI 1.007-1.637, p=0.043) were also independent predictors for low BMD. Conclusion: Even with some limitations such as the small number for the study population, a single center experience, and a crosssectional design, we recommend that clinical immunologists should be alert for diminished BMD in CVID patients, especially those with low folic acid and high ALP levels and lymphopenia.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41786582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dress Syndrome 着装综合症

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-04-30 DOI: 10.21911/aai.444

S. Bahçeci, Demet Can

{"title":"Dress Syndrome","authors":"S. Bahçeci, Demet Can","doi":"10.21911/aai.444","DOIUrl":"https://doi.org/10.21911/aai.444","url":null,"abstract":"Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) is a rare, idiosyncratic, life-threatening drug reaction with a variety of clinical manifestations including symptoms of fever higher than 38.5 oC, pruritic maculopapular or erythematous eruption, hematologic abnormalities, lymphadenopathy, and multiorgan involvement. Its incidence ranges from 1 in 1000 to 1 in 10,000 drug exposures, and it has an estimated mortality rate of up to 10%. To date, many drugs have been reported to cause DRESS syndrome, but the most common ones are the anticonvulsants and sulfonamides, although the pathogenesis is not clearly understood. Deficiency or defects in the epoxide hydroxylase enzyme, which detoxifies the metabolites of aromatic anticonvulsants, an insufficiency in the detoxification of the drug leading to reactive metabolites which may trigger immunologic reactions, predispositions due to some HLA alleles, and reactivation of herpes viruses are suggested to play a role in the pathogenesis. The latent period varies from two to six weeks. Hematologic, hepatic, renal, cardiac, pulmonary, neurologic, gastrointestinal and endocrine involvement; and hemophagocytic syndrome can be seen during the clinical course of DRESS syndrome. The long term sequels of DRESS syndrome include hepatic, renal and adrenal failure; diabetes mellitus type 1 and type 2, Graves disease, autoimmune hemolytic anemia, lupus, systemic sclerosis, and autoimmune enteropathy. Diagnosis of DRESS syndrome is difficult to establish, and requires a high degree of initial clinical suspicion and ruling out of other etiologies. The most important step in the management of DRESS syndrome is early diagnosis and prompt withdrawal of the offending drug. In cases with organ involvement, systemic corticosteroid treatment is required. In serious and steroid-resistant cases, using more potent immunosuppressive agents or intravenous immunoglobulin treatments may be required.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43439599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Five Years of Experience in a Single Center: Retrospective Analysis of Adult Patients with Common Variable Immunodeficiency 在单一中心的五年经验:对成人常见变异性免疫缺陷患者的回顾性分析

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-04-17 DOI: 10.21911/aai.504

G. Aytekin, Eray Yıldız, Fatih Çölkesen, Ş. Arslan, A. Çalışkaner

{"title":"Five Years of Experience in a Single Center: Retrospective Analysis of Adult Patients with Common Variable Immunodeficiency","authors":"G. Aytekin, Eray Yıldız, Fatih Çölkesen, Ş. Arslan, A. Çalışkaner","doi":"10.21911/aai.504","DOIUrl":"https://doi.org/10.21911/aai.504","url":null,"abstract":"Objective: Common Variable Immune Deficiency (CVID) is a heterogeneous immune disorder characterized by impaired and/or inadequate B cell differentiation with hypogammaglobulinemia. It is characterized by frequent and recurrent respiratory infections, autoimmune disorders, chronic lung diseases, granulomatous diseases, and increased risk for lymphoid malignancies. Materials and Methods: The medical records of 47 patients (22 females, 25 males) who had been followed up at our clinic and had sufficient data in their files were retrospectively reviewed. Patients were diagnosed with CVID according to the ESID (European Society for Immunodeficiency) criteria. Results: The median age of the patients was 32 (19-65) years. The most frequent clinical presentation of the patients was with recurrent upper respiratory infections (46%), pneumonia (29.8%), otitis media (23.4%) and chronic sinusitis (17%). During the follow-up period, 17 patients (36.8%) developed autoimmune complications, 14 (29.8%) of whom had autoimmune cytopenia. A total of 26 patients (55.3%) had bronchiectasis confirmed with computed tomography of the thorax. Lymphopenia was detected in 13 patients (27.7%). The median immunoglobulin level at the time of diagnosis was IgG 2.77 (0.33-6.90) g/L, IgM 0.31 (0.06-5.99) g/L, and IgA 0.25 (0.01- 5.02) g/L. Conclusion: CVID is very heterogeneous in terms of both clinical and laboratory features. Moreover, it is more common than expected, particularly in adulthood. The centers dealing with CVID should share their experiences in order to increase awareness among physicians.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46755296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Asthma and COVID-19 哮喘和COVID-19

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-04-17 DOI: 10.21911/aai.531

E. Çelebioğlu

{"title":"Asthma and COVID-19","authors":"E. Çelebioğlu","doi":"10.21911/aai.531","DOIUrl":"https://doi.org/10.21911/aai.531","url":null,"abstract":"Objectives: Highlight the asthma situation in this pandemic. Describe the safety aspects of patients and health professionals. Discuss its severity, control, risk factors, therapeutic management of chronic disease and its exacerbations. Methods: Data were collected from the scientific literature on the topic asthma in the context of the COVID-19 pandemic. A search was performed in PubMed databases, using the descriptors: asthma, coronavirus infections, pandemics, risk factors, drug therapy and spirometry. Results: Asthma has not been identified as a significant risk factor for severe COVID-19 disease, perhaps due to the lower expression of angiotensin-converting enzyme receptors in atopic asthma. Groups were identified, among severe asthmatics, with greater expression of these receptors. Conclusions: Nebulizers should be avoided, spacers should not be shared and spirometry or peak expiratory flow measurement is not recommended. All asthmatics should be maintained on inhaled corticosteroids. Short-acting beta2-agonist only treatment is not recommended from the age of 12. As-needed low dose inhaled corticosteroid with formoterol is the prefered reliever for this age group and can be offered together on the same device. From 6 to 11-years-old, reliever medication should preferably be short-acting beta2-agonists, associated with low dose inhaled corticosteroids and applied in separate devices. In severe asthma, tiotropium should precede the indication of the immunobiological and this, when in use, should not be interrupted.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44790967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Chronic (Cold) Contact Urticaria Treated Successfully with Anti-IgE (Omalizumab) 抗ige (Omalizumab)治疗慢性(感冒)接触性荨麻疹成功

IF 0.2

Astim Allerji Immunoloji Pub Date : 2020-04-17 DOI: 10.21911/AAI.455

Ö. Özdemir

{"title":"Chronic (Cold) Contact Urticaria Treated Successfully with Anti-IgE (Omalizumab)","authors":"Ö. Özdemir","doi":"10.21911/AAI.455","DOIUrl":"https://doi.org/10.21911/AAI.455","url":null,"abstract":"A 15-year-old male patient presented with complaints of erythema, urticaria and burning on the hands, feet and trunk after contact with cold objects, liquids and/or air for the last two-years. There was no mucosal site involvement and no associated symptoms. The physical examination was normal. The cold provocation test was positive. Biochemistry, hemogram, ESR, CRP, urine analysis, stool examination, latex specific IgE, RF, ANA, skin prick test with common aeroallergens including dust mites, yeasts, animal allergens, various tree and grass pollens, and the serum specific IgE, C3, C4, thyroid function tests, cryoglobulins, cold agglutinins, HIV and HBsAg testing demonstrated normal/negative results. The total IgE level was 5.520 IU/ml in the beginning but decreased to 2.150 IU/ml after 15 months. Due to chronicity of his symptoms and the lack of a triggering factor other than cold, he was diagnosed with type I cold contact urticaria (CCU). Despite using different antihistamines for 10 months, his have persisted. With the use of subcutaneous omalizumab at the dose of 300 mg/month, the symptoms were under control after 3 months (urticaria activity score and Omalizumab was well tolerated. and particularly the severe form (type III) has a considerable effect on the quality of no to been there is no biomarker to predict the response to omalizumab. This case report shows that omalizumab could be useful for the CCU patients.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2020-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48797757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An Indolent Cause of Recurrent Anaphylaxis with NSAIDs: Systemic Mastocytosis 非甾体抗炎药引起复发性过敏反应的惰性原因:全身肥大细胞增多症

IF 0.2

Astim Allerji Immunoloji Pub Date : 2019-12-28 DOI: 10.21911/AAI.447

G. Aytekin, S. Fındık, Fatih Çölkesen, Eray Yıldız, A. Çalışkaner

引用次数: 0